Status:
UNKNOWN
Effect Study of Tigecycline to Treat Severe Sepsis and Septic Shock
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Collaborating Sponsors:
Zhejiang Hisun Pharmaceutical Co. Ltd.
Conditions:
Abdominal Infection
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
PHASE3
Brief Summary
Selection of tigecycline in severe sepsis and septic shock patients in empirical antibiotic therapy (Hai Zheng Energy Star ®) combined with piperacillin / tazobactam (tazocin ®) scheme, compared with ...
Detailed Description
Tigecycline as representative glycylcycline antibiotics, has wide antibacterial spectrum and strong antibacterial activity, tigecycline in almost all of the gram positive bacteria and most gram negati...
Eligibility Criteria
Inclusion
- Be consistent with severe sepsis and septic shock diagnosis standards
- Age above 18 years old, is expected in more than 5 days in ICU
- APACHEⅡ score\>15
- By the patients themselves or their authorized person agreed to participate in the clinical trial and signed the informed consent
Exclusion
- Allergic to penicillin, or of tigecycline allergic patients
- Patients with abnormal liver function is severe
- Be pregnant or lactating women
- Be not signed the informed consent of patients
- Any can be expected to increase patient risk or other factors can interfere with the results of a clinical trial
Key Trial Info
Start Date :
May 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2017
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT02191475
Start Date
May 1 2014
End Date
May 1 2017
Last Update
July 16 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
TianjinCIH
Tianjin, Tianjin Municipality, China, 300060